×
Contact Us

Contact Us

Please contact us below with any questions

info@quadratech.co.uk

+44 (0)33 3321 2371

Side Contact
quadratech Logo
Next Day & International Delivery
Competitive Pricing
Over 30 Years Experience
Based In The UK

SARS-CoV-2 Nucleoprotein, His-Tag (E. coli): Biotin Conjugate (100µg) (Special Terms Apply*)

SARS-CoV-2 Nucleoprotein, His-Tag (E. coli): Biotin Conjugate (100µg) (Special Terms Apply*)

×

We're always working hard to give our customers as much information on products and the best price possible. If you need any assistance or would like a quote please contact us and we will be happy to help

Product Brand:
Product Code: QTXAG-652-100
Description

Product Summary:

SARS-CoV-2 Nucleoprotein, His-Tag (E. coli): Biotin Conjugate (100µg) (Special Terms Apply*) (QTXAG-652-100) is SARS-CoV-2 Nucleoprotein is a recombinant antigen manufactured in E. coli cells to high purity for use in vaccine research and immunoassay development. Horseradish peroxidase (HRP) and Biotin conjugated protein is also available for use in immunochemical assays. SARS-CoV-2, previously known as the 2019 Novel Coronavirus (2019-nCoV), causes the pandemic COVID-19 disease.

SARS-CoV-2 Nucleoprotein (E. coli) is a recombinant antigen manufactured to high purity. SARS-CoV-2, previously known as the 2019 Novel Coronavirus (2019-nCoV), causes the pandemic COVID-19 disease.

*Special Terms: Please see product specification details below and our Ordering page for details.

Product Specification
Product Code
QTXAG-652-100
Product Name
SARS-CoV-2 Nucleoprotein, His-Tag (E. coli): Biotin Conjugate (100µg) (Special Terms Apply*)
Product Category
Product Brand
Product Analyte or Application
Product IVD Registration Status
Research Use Only - RUO
Product Size
1 x 100 µg
Related products

Our Accreditations

Logo showing information of 3core2 ISO9001:2015 accreditation information as per IAS International Accreditation Service standards on a transparent background.
ISO 9001 2015 Certified Logo Horizontal with White Background
Receive Our Latest News
Sign Up To Our Newsletter